Summary
Uniform drug treatments are not always the best option for treating some patient populations – including children and the elderly. The industry now has extensive knowledge on the benefits of personalized medicines that take the age, metabolic and genetic differences of patients into account. However, until now there has not been a practical manufacturing solution to put this knowledge into wide-scale use.
CurifyLabs has created a technology called MiniLab to make high-quality 3D printing of personalized medicines available on site in the pharmacies and bring industry level standards to mass customisation of medicines. In this project we will finalize a standard process for developing 3D printing compatible formulations and quality control solutions. This will make MiniLab highly scalable across different therapeutic areas.
CurifyLabs has created a technology called MiniLab to make high-quality 3D printing of personalized medicines available on site in the pharmacies and bring industry level standards to mass customisation of medicines. In this project we will finalize a standard process for developing 3D printing compatible formulations and quality control solutions. This will make MiniLab highly scalable across different therapeutic areas.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190157849 |
| Start date: | 01-09-2023 |
| End date: | 31-08-2025 |
| Total budget - Public funding: | 3 542 500,00 Euro - 2 479 750,00 Euro |
Cordis data
Original description
Uniform drug treatments are not always the best option for treating some patient populations – including children and the elderly. The industry now has extensive knowledge on the benefits of personalized medicines that take the age, metabolic and genetic differences of patients into account. However, until now there has not been a practical manufacturing solution to put this knowledge into wide-scale use.CurifyLabs has created a technology called MiniLab to make high-quality 3D printing of personalized medicines available on site in the pharmacies and bring industry level standards to mass customisation of medicines. In this project we will finalize a standard process for developing 3D printing compatible formulations and quality control solutions. This will make MiniLab highly scalable across different therapeutic areas.
Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)
